Huntington Bancshares Incorporated (NASDAQ:HBAN) in last trading activity advanced 0.36% to close at $11.10. Company weekly performance is 0.82% while its quarterly performance stands at 9.47%. Huntington Bancshares Incorporated (NASDAQ:HBAN) is -1.77% away from its 52 week high. Hilliard Lyons began coverage on shares of Huntington Bancshares (NASDAQ:HBAN) in a report issued on Tuesday. The firm issued a buy rating and a $12.00 target price on the stock.
On last trading day Whitestone REIT (NYSE:WSR) moved down -0.25% to close at $15.98. Its volatility for the week is 1.75% while volatility for the month is 1.85%. WSR’s sales growth for past 5 years was 17.20% and its EPS growth for past 5 years was -11.70%. Whitestone REIT (NYSE:WSR) monthly performance is 5.20%. Whitestone REIT (NYSE:WSR) announced a $6.3 million acquisition of City View Village in San Antonio, Texas, which is strategically located across from The Strand of Huebner Oaks acquired by Whitestone last year. This acquisition is the third Community Centered PropertyTM in the San Antonio market and highlights Whitestone’s commitment to expand its portfolio in core markets and focus on local, serviced-based tenants catering to the surrounding neighborhoods.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) belongs to Healthcare sector. Its weekly performance is 12.50%. On last trading day company shares ended up $1.35. Cytori Therapeutics, Inc. (NASDAQ:CYTX) distance from 50-day simple moving average (SMA50) is 52.44%. Cytori Therapeutics Inc. (NASDAQ:CYTX) announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma.
Mylan N.V. (NASDAQ:MYL) shares increased 1.86% in last trading session and ended the day at $59.57. MYL Gross Margin is 46.30% and its return on assets is 6.00%. Mylan N.V. (NASDAQ:MYL) quarterly performance is 6.91%. Mylan N.V. (NASDAQ:MYL) announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott’s Generess® Fe Tablets. Mylan’s partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan’s immediate shipment of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable) represents the company’s ninth oral contraceptive product launch in the U.S.
On last trading day EMCOR Group Inc. (NYSE:EME) moved down -0.02% to close at $46.46. Its volatility for the week is 1.41% while volatility for the month is 1.94%. EME’s sales growth for past 5 years was 4.20% and its EPS growth for past 5 years was 2.80%. EMCOR Group Inc. (NYSE:EME) monthly performance is 4.90%. EMCOR Group Inc. (NYSE:EME) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.08 per common share. The dividend will be paid on April 29, 2015 to stockholders of record as of April 17, 2015.